

Results Presentation 3Q FY Ending March 2022

Win-Partners Co., Ltd. (3183)

3Q results to December 2021




- The number of cases recovered in major segments
- Reinforced rebate-programs/price negotiations enabled GPM to continue improving
- With a moderate increase in SGA expenses, OP for the period increased substantially YoY

Consolidated results summary

(¥mil) 3Q to	Dec 2020	Dec 2021	YoY(%)
Sales	44,470	48,855	+9.9
Operating profit	1,470	2,147	+46.1
Recurring profit	1,478	2,153	+45.6
Net profit	995	1,462	+46.9
EPS (yen)	34.67	50.93	_
BPS (yen)	716.63	753.34	_

Highlights (sales)



- The number of cases increased in the main segments
- Sales increased YoY in all segments


Sales breakdown by segment

Segment	Sales	YoY growth(%)		% of sales
Segment	(¥mil)	Volume	Value	(%)
Percutaneous coronary intervention (PCI)	12,885	+5.2	+8.5	26.4
Cardiac rhythm segment (CRS)	12,919	+5.0	+5.9	26.4
Cardiac vascular segment (CVS)	7,330	+9.5	+14.7	15.0
Percutaneous peripheral intervention (PPI)	2,828	+9.5	+10.9	5.8
Neurovascular	2,124	+5.5	+5.4	4.3
Diabetes mellitus segment (DMS)	2,104	-	+15.5	4.3
Medical equipment	4,588	-	+22.6	9.4
Others	4,074	-	+5.2	8.3
Total	48,855	-	+9.9	100.0

Segment review

ΡСΙ	 PTCA balloon/DES sales increased due to the higher number of cases Gained new customers
C R S	 Pacemaker sales increased due a recovery in the number of cases ABL-related sales continued to increase
C V S	 Structural heart disease (SHD) including TAVI sales maintained strong growth
ΡΡΙ	 Shunt PTA sales grew due to an increase in the number of patients DCB sales increased due to a new manufacturer in the market and the expansion of applications
Neuro- vascular	- Sales of thrombectomy devices for urgent treatment saw growth
Medical equip- ment	 Large-scale medical equipment sales increased Obtained COVID-19 related orders
DMS	 Sales of blood glucose measuring equipment and insulin pumps continued to increase

Highlights (operating profit)



• Gross profit margins 12.7% (+0.5 pp YoY)

- The number of cases recovered
- Rebate programs and price negotiations with suppliers were intensified

• SGA +3.1% YoY

- Labor cost +2.5% YoY
- Number of employees: 545 (Dec 2020) \rightarrow 553 (Dec 2021)

Consolidated income statements

	Dec 2020		Dec 2021	
	(¥mil)	(%)	(¥mil)	(%)
Sales	44,470	100.0	48,855	100.0
Cost of sales	39,041	87.8	42,626	87.3
Gross profit	5,429	12.2	6,228	12.7
SG&A expenses	3,958	8.9	4,080	8.4
Operating profit	1,470	3.3	2,147	4.4
Non-operating profit	9	0.0	6	0.0
Non-operating expenses	0	0.0	0	0.0
Recurring profit	1,478	3.3	2,153	4.4
Extraordinary profit	0	0.0	0	0.0
Extraordinary loss	19	0.0	0	0.0
Pretax profit	1,459	3.3	2,153	4.4
Taxes	463	1.0	691	1.4
Net profit	995	2.2	1,462	3.0

Consolidated balance sheet

	Mar 2021		Dec 2021		Change
	(¥mil)	(%)	(¥mil)	(%)	(¥mil)
Current assets	35,994	89.6	36,480	89.3	+486
Cash and deposits	17,122	42.6	17,359	42.5	+237
Accounts receivable	15,966	39.7	16,141	39.5	+175
Inventories	2,334	5.8	2,368	5.8	+34
Other current assets	571	1.4	611	1.5	+40
Fixed assets	4,193	10.4	4,387	10.7	+194
Total assets	40,187	100.0	40,867	100.0	+680
Current liabilities	17,960	44.7	18,082	44.2	+122
Accounts payable	16,756	41.7	17,055	41.7	+299
Taxes payable	277	0.7	399	1.0	+122
Other current liabilities	926	2.3	627	1.5	-299
Fixed liabilities	1,088	2.7	1,158	2.8	+70
Total liabilities	19,049	47.4	19,240	47.1	+191
Net assets	21,138	52.6	21,627	52.9	+489
Total liabilities,	40,187	100.0	40,867	100.0	+680
net assets					

10

Outlook for 3/2022

Consolidated earnings forecasts to March 2022 (unchanged from the initial forecast)

	(¥mil)	YoY(%)	(%)
Sales	64,500	+3.8	100.0
Operating profit	2,500	+10.9	3.9
Recurring profit	2,500	+10.3	3.9
Net profit	1,700	+10.3	2.6
EPS (yen)	59.22		
DPS (yen)	35.00		

Highlights (sales)




- The full-year forecast is left unchanged given the recent rapid spread of the COVID-19 pandemic
- Continue focusing on gaining new customers and expanding sales at existing customers

Sales forecast by segment

	(¥mil)	YoY(%)	% of sales
Percutaneous coronary intervention (PCI)	17,590	+10.1	27.3%
Cardiac rhythm segment (CRS)	17,420	+6.5	27.0%
Cardiac vascular segment (CVS)	9,270	+6.9	14.4%
Percutaneous peripheral intervension (PPI)	3,650	+5.2	5.6%
Neurovascular	2,970	+9.3	4.6%
Diabetes mellitus segment (DMS)	2,650	+6.5	4.1%
Medical equipment*	5,600	-9.6	8.7%
Other	5,350	-14.4	8.3%
Total	64,500	+3.8	100.0%

Highlights (operating profit)

YoY +10.9%




Forecast of gross profit margins: 12.8% (+0.3 pp YoY)

- Continue intensifying price negotiations and rebate programs with suppliers
- Focus on a limited number of devices to offer
- Switch to higher margin devices

• SG&A ¥5.72bn (+4.4% YoY)

Forecast of the number of group employees:
 547 (Mar 2021) → 579 (Mar 2022 – unchanged from the initial plan)

Highlights (net profit)



• CapEx ¥70 mil vs. ¥1.17bn for FY 3/2021

• Depreciation ¥160 mil vs. ¥194 mil for FY 3/2021

How WIN is approaching major challenges

Promotion of a logistics revolution

- Support for the experimental study on RFID tags on medical devices ongoing
- Held a groundbreaking ceremony for WIN Heart Gate in November

Focus on CRS

- Start an education course for "ablation specialists"
- Increase CDRs (Cardiac Device Representatives) (95 in Dec 2021 vs. 90 in Sep 2021)

• M&As, etc.

- Continue investigating opportunities in order to expand the business
- Continue to enhance operational efficiency with RPA

Aim of WIN Heart Gate

Achieve higher logistics efficiency by covering all sales bases in the metropolitan area


Separate sales and logistics

• Utilize RFID

- Improve the efficiency of inventory control
- Enhance the traceability of medical devices
- Reduce inventory loss

• Reduce distribution costs, etc.

Location of WIN Heart Gate




WIN Heart Gate

Distribution facilities of medical equipment manufacturers (Source: WIN Partners)

Close to distribution facilities of medical device manufacturers

How WIN Heart Gate will work



ESG efforts

Sustainability Policy


Under the corporate philosophy of "The WIN-Partners group offers better quality of life to all and contributes to creating an affluent society," WIN-Partners group, with consideration for all stakeholders, will make efforts to resolve challenges that society faces and will contribute to developing a sustainable society.

Sustainability Committee

Promote activities for sustainability, including an assessment of the risks of climate change and the scope of impact


Dividends & payout ratio

+1 yen from March 2021





Trends in the number of cases



Reimbursement prices of major products

Cognost	Compared		Reimbursement prices (¥000)	
Segment	Items -	2019 (Oct)	2020 (Apr)	Change (%)
	PTCA balloon catheter	38	35	- 8.7
PCI	Drug eluting stent (DES)	173	161	- 6.9
	Intravascular ultrasound (IVUS) catheter	84	80	- 4.6
	Pacemaker	763	720	- 5.6
	Implantable cardioveter defibrillator (ICD)	2,950	2,950	0.0
CRS	Cardiac resychronization therapy defibrillator (CRTD)	3,990	3,990	0.0
CKS	Subcutaneous implantable defibrillator (S-ICD)	3,120	3,120	0.0
	Ablation catheter	126	124	- 1.6
	Cardiac cryoablation catheter	649	649	0.0
	Stent graft (abdomen)	1,320	1,320	0.0
CVS	Open stent graft	1,110	1,110	0.0
	Heart valve for transcatheter aortic valve implantation (TAVI) (balloon-expandable)	4,510	4,510	0.0
	Heart valve for TAVI (self-expandable)	3,740	3,740	0.0
	PTA balloon catheter	56	55	- 1.6
PPI	Peripheral vascular stent	175	174	- 0.6
	Peripheral drug eluting stent (DES)	233	233	0.0
Neuro-	Embolic coil (electric type)	118	118	0.0
vascular	Thrombectomy catheter (self-expandable)	386	386	0.0

About WIN-Partners

Company profile

Code:	3183 (TSE 1st)
Headquarters:	21F, KYOBASHI EDOGRAND 2-2-1, Kyobashi, Chuo-ku, Tokyo 104-0031
Capital:	550 million yen
Business:	Distribution of medical devices (consolidated basis)
Board of management:	Hideumi Akizawa, CEO, and 8 directors, including 4 outside directors
Subsidiaries:	Win International, TESCO, MCI (100% owned)
No of employees:	553 (consolidated basis) as of Dec 2021
No. of shares:	30,503,310, including 1,795,073 treasury shares

Our philosophy and vision

Our philosophy

The WIN-Partners group offers a better quality of life to all and contributes to creating an affluent society.

Our mission is to contribute to a better healthy life expectancy for all so that people can live healthy and fulfilling lives.

Our vision

We aim to be a leading company of the next-generation medical business, creating new demand and new markets.


As medical and information technologies progress, we aim to improve the earnings of both existing and new customers and to expand market shares, beyond existing medical services and business models. We welcome companies that share our corporate philosophy and take a leadership position to achieve sustainable growth and industry consolidation, which will lead to higher operational efficiency in the medical industry.

Independent medical device distributor group




29


History



Growing with the expansion of minimally invasive treatment




Major products




Track record of quarterly results

Trends in sales/operating profit (quarterly)



= Year of reimbursement price revisions

Share prices





Disclaimer

This material was prepared based on the information available and the views held at the time it was made. Statements in this material that are not historical facts, including but not limited to plans, forecasts and strategies are "forward-looking statements." Forward-looking statements are by their nature subject to various risks and uncertainties, including not limited to a decline in general economic conditions, general market conditions, technological developments, changes in customer demand for products and services, increased competition, and other important factors, each of which may cause actual results and future developments to differ materially from those expressed or implied in any forward-looking statement.

With the passage of time, the information in this material (including but not limited to forward-looking statements) could be superseded or cease to be accurate. WIN-Partners Co., Ltd. disclaims any obligation or responsibility to update, revise, or supplement any forward-looking statement or other information in any material or generally to any extent. The utilization of or reliance on the information in this material is at your own risk.

Contact

WIN-Partners Co., Ltd. Investor Relations Phone: +81-3-3548-0790 http://www.win-partners.co.jp